Genome editing company Editas, backed by Alphabet and Partners Healthcare, has secured $94.4m, pricing the initial public offering at the bottom of the $16 to $18 range.
Editas Medicine, a US-based genome editing technology developer backed by internet and technology conglomerate Alphabet, has priced what is the first initial public offering in the US in 2016, Reuters reported yesterday.
Editas raised $94.4m after pricing 5.9 million shares at the bottom of the $16 to $18 range it set last week, according to a person familiar with the matter. It is now valued at $571m.
Founded in 2013, Editas is working on a genome editing platform based on…
